Startups
Edit
VeriStrat
http://www.veristratsupport.com/Last activity: 12.01.2015
Active - Reference to Biodesix Inc.
VeriStrat is a blood test for patients with advanced non-small cell lung cancer (NSCLC) that detects proteins which may be associated with your cancer. VeriStrat test results provide your doctor with information to help make more informed treatment decisions, based on new insight into how you may benefit from your available treatment options.
VeriStrat is for patients with advanced NSCLC who are EGFR wild-type or whose EGFR mutation status is unknown. The test is used in patients who have progressed after 1st-line treatment or are ineligible for platinum-based chemotherapy. Test results should be used in combination with the patient’s clinical history, other diagnostic tests, and clinicopathological factors, evaluated by a qualified physician. VeriStrat is not an EGFR mutation test.
VeriStrat is a clinically validated diagnostic test that helps physicians guide therapeutic decisions for patients with advanced NSCLC. Results from PROSE, a prospective, randomized phase III clinical trial, showed that VeriStrat testing helps physicians choose between chemotherapy and oral erlotinib therapy.
To learn more about VeriStrat, please visit us at www.VeriStratSupport.com.
VeriStrat is for patients with advanced NSCLC who are EGFR wild-type or whose EGFR mutation status is unknown. The test is used in patients who have progressed after 1st-line treatment or are ineligible for platinum-based chemotherapy. Test results should be used in combination with the patient’s clinical history, other diagnostic tests, and clinicopathological factors, evaluated by a qualified physician. VeriStrat is not an EGFR mutation test.
VeriStrat is a clinically validated diagnostic test that helps physicians guide therapeutic decisions for patients with advanced NSCLC. Results from PROSE, a prospective, randomized phase III clinical trial, showed that VeriStrat testing helps physicians choose between chemotherapy and oral erlotinib therapy.
To learn more about VeriStrat, please visit us at www.VeriStratSupport.com.
Mentions in press and media 5
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 14, 2014 | Biodesix Raises Additional $6.1M in Series E Funding | Biodesix, Inc., a Boulder, CO-based molecular diagnostic company dedicated to personalizing medicine, raised an additional $6.1m in Series E funding. This added to the $8.3m first close of the round announced a month ago (read here) with pr... |
| Dec 2, 2013 | Biodesix Closes $8.3M Series E Equity Financing | Biodesix, a Boulder, CO-based molecular diagnostic company dedicated to personalizing medicine, closed an $8.3m Series E equity financing. New funds accounted for $4.3m and the remaining $4m came from the conversion of a convertible note. E... |
| Apr 12, 2013 | Biodesix Secures $8.8M Series D | BOULDER, CO, Molecular diagnostics company closed on $8.8 million in a follow-on sale of its Series D preferred shares. >> Click here for more funding data on Biodesix >> To export Biodesix funding data to PDF and Excel, cli... |
| Apr 12, 2013 | Biodesix Closes $8.8M Series D Financing | Biodesix, Inc., a Boulder, CO-based molecular diagnostics company advancing the development of innovative products for personalizing medicine, closed on $8.8m in Series D financing. Backers included unnamed existing shareholders. Led by CEO... |
Reviews 0
FAQ about VeriStrat
What has the press written about VeriStrat?
Parsers VC has collected 5 articles mentioning VeriStrat, among them “Biodesix Raises Additional $6.1M in Series E Funding” (Jan 14, 2014) and “Biodesix Closes $8.3M Series E Equity Financing” (Dec 2, 2013).
Is VeriStrat still active?
Yes, VeriStrat is active; its latest activity on Parsers VC dates from Jan 12, 2015.